10-K: Exelixis Reports Strong 2024 Results, Advances Pipeline with Focus on Zanzalintinib

Exelixis reports its eighth consecutive year of profitability with 11% revenue growth, driven by increased sales of cabozantinib and progress in its zanzalintinib development program.

Summary

• Exelixis reported its 2024 financial results, marking its eighth consecutive year of profitability.
• Net product revenues increased by approximately 11% year-over-year, driven by increased sales of cabozantinib products in the U.S.
• Royalties earned from collaboration agreements with ex-U.S. partners increased by approximately 12% year-over-year.
• The company is advancing its pipeline, with a focus on zanzalintinib, a novel tyrosine kinase inhibitor (TKI) currently in late-stage clinical development.
• Exelixis is also progressing other pipeline programs, including XL309, XB010, and XL495, each with best-in-class potential.
• The company is expanding its oncology product pipeline through drug discovery efforts, research collaborations, in-licensing arrangements, and other strategic transactions.
• Exelixis is actively seeking patent protection for its product candidates and related technologies in the U.S., EU, and other foreign jurisdictions.
• The company is committed to maintaining a diverse workforce and fostering a culture of inclusion.
• Exelixis is subject to healthcare laws, regulations, and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and pipeline advancements. While acknowledging risks, the overall tone is optimistic and confident in the company's future prospects.

Positives

• The company achieved its eighth consecutive year of profitability.
• Net product revenues increased by approximately 11% year-over-year.
• The company is advancing its pipeline, with a focus on zanzalintinib.
• The FDA accepted Exelixis' sNDA seeking approval for cabozantinib to treat adult patients with previously treated, locally advanced/unresectable or metastatic, wellor moderately differentiated pNET or epNET, and assigned a PDUFA target action date of April 3, 2025.
• The company initiated a phase 1 clinical trial evaluating XB010, its first ADC advanced internally.
• The Board of Directors authorized the repurchase of up to $500 million of the company's common stock through the end of 2025.

Negatives

• The company elected to terminate its collaboration agreement with Cybrexa Therapeutics, LLC and relinquish all rights with respect to CBX-12.
• The company will discontinue the development of XB002, its tissue factor (TF) targeting ADC.
• The company announced the final analysis for the secondary endpoint of OS for COSMIC-313, a phase 3 pivotal trial evaluating the combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediateor poor-risk RCC, which demonstrated that the experimental arm did not demonstrate an OS benefit over the control arm.

Risks

• The company's ability to grow is dependent on the commercial success of CABOMETYX and the continued development of the cabozantinib franchise.
• The company may be unable to expand its discovery and development pipeline, which could limit its growth and revenue potential.
• Clinical testing of cabozantinib for new indications, or of the company's other new product candidates, is a lengthy, costly, complex, and uncertain process.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain, and subject to change.
• The company's profitability could be negatively impacted if expenses associated with its activities grow more quickly than the revenues it generates.
• The company's clinical, regulatory, and commercial collaborations with major companies make it reliant on those companies for their continued performance and investments.
• The company is subject to healthcare laws, regulations, and enforcement, as well as laws and regulations relating to privacy, data collection, and processing of personal data.
• Data breaches and other cybersecurity incidents impacting the company's information technology operations and infrastructure could compromise its intellectual property or other sensitive information.
• If the company is unable to adequately protect its intellectual property, third parties may be able to use its technology.
• The loss of key personnel or the inability to retain and attract additional personnel could impair the company's ability to operate successfully.
• The company's goals and disclosures related to environmental, social, and governance matters subjects it to risks, including risks to its market perception and stock price.

Future Outlook

Exelixis projects that net product revenues may increase in fiscal year 2025, as compared to 2024. The company also projects that research and development expenses may increase for fiscal year 2025, as compared to the prior year. The company projects that selling, general and administrative expenses may increase in fiscal year 2025, as compared to 2024.

Industry Context

The report highlights the competitive landscape in the oncology market, with several novel therapies and combinations of therapies being approved or in advanced stages of clinical development. This underscores the need for Exelixis to continue innovating and differentiating its products to maintain a competitive edge.

Comparison to Industry Standards

• The report mentions several competitors in the RCC, HCC, DTC, and MTC markets, including Merck, Pfizer, BMS, Eisai, Bayer, and Novartis.
• CABOMETYX is positioned as a leading TKI treatment option for patients with advanced RCC, demonstrating statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in clinical trials.
• The combination of CABOMETYX with nivolumab is included in the NCCN Clinical Practice Guidelines for Kidney Cancer as a Category 1 preferred option for the first-line treatment of patients with clear cell RCC across all risk groups.
• CABOMETYX is also included in the NCCN Clinical Practice Guidelines for Hepatocellular Carcinoma as a Category 1 option for the treatment of patients with HCC as a subsequent-line systemic therapy if disease progression occurs.

Management Changes

Legal Proceedings

• The company is involved in patent litigation with MSN, Teva, Cipla and Sun regarding generic versions of CABOMETYX tablets.
• The company received from several covered entities a 340B Program Administrative Dispute Resolution (ADR) petition, seeking to invoke an administrative adjudication process overseen by the HHS Health Resources and Services Administration (HRSA).

Stakeholder Impact

• The company's performance impacts shareholders through stock value and potential dividends.
• Employees are affected by workforce restructuring and compensation packages.
• Patients benefit from the development and commercialization of new cancer therapies.
• Collaboration partners are impacted by the company's decisions regarding development and commercialization strategies.

Next Steps

• The company intends to apply to CMS to maintain the small biotech exception each year through 2030.
• The company continues to evaluate the timing of a potential regulatory submission to the FDA for CONTACT-02.
• The company intends to initiate additional pivotal trials evaluating zanzalintinib across a broad array of future potential indications, including in STELLAR-311, a planned phase 3 pivotal trial evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin, which we anticipate initiating in the first half of 2025.
• The company expects to progress up to three new development candidates into preclinical development during 2025.

Key Dates

Keywords

cabozantinib, zanzalintinib, Exelixis, oncology, clinical trials, FDA, pharmaceutical, pipeline, development, commercialization, cancer, RCC, HCC, DTC, NET, mCRPC, SCCHN, CRC, biotherapeutics, ADC